Pfizer sets aside $772M for Prempro cases, but warns of uncertainties of litigation
This article was originally published in Scrip
Executive Summary
Pfizer has reported that it expects to pay at least $772 million to resolve the product liability litigation related to its hormone replacement therapy Prempro, according to a filing with the US Securities and Exchange Commission.